Paper29463528
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R and 10 others. Antimicrob Agents Chemother, 2018. Cited by 21 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Papers, record 29463528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29463528
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Piperacillin | Major topic |
| Pseudomonas aeruginosa | Major topic |
| Tobramycin | Major topic |
| Humans | |
| Microbial Sensitivity Tests | |
| Models, Theoretical |
Source PubMed
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20,000,886 | Augmented renal clearance: implications for antibacterial dosing in the critically ill. | Clin Pharmacokinet | 2010 | https://conductscience.org/library/papers/20000886 | PubMed |
| 2 | 20,463,340 | Hospital-acquired infections due to gram-negative bacteria. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20463340 | PubMed |
| 3 | 28,264,846 | Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28264846 | PubMed |
| 4 | 24,760,199 | Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. | J Infect Dis | 2014 | https://conductscience.org/library/papers/24760199 | PubMed |
| 5 | 26,433,783 | Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. | J Antimicrob Chemother | 2016 | https://conductscience.org/library/papers/26433783 | PubMed |
| 6 | 6,794,444 | Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6794444 | PubMed |
| 7 | 10,868,299 | [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa]. | Jpn J Antibiot | 2000 | https://conductscience.org/library/papers/10868299 | PubMed |
| 8 | 29,180,527 | Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29180527 | PubMed |
| 9 | 24,429,437 | DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? | Clin Infect Dis | 2014 | https://conductscience.org/library/papers/24429437 | PubMed |
| 10 | 6,810,755 | Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6810755 | PubMed |
| 11 | 3,909,952 | Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. | Antimicrob Agents Chemother | 1985 | https://conductscience.org/library/papers/3909952 | PubMed |
| 12 | 7,637,145 | The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. | JAMA | 1995 | https://conductscience.org/library/papers/7637145 | PubMed |
| 13 | 19,157,339 | You only find what you look for: the importance of high creatinine clearance in the critically ill. | Anaesth Intensive Care | 2009 | https://conductscience.org/library/papers/19157339 | PubMed |
| 14 | 20,516,275 | Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20516275 | PubMed |
| 15 | 25,632,974 | Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? | Crit Care | 2015 | https://conductscience.org/library/papers/25632974 | PubMed |
| 16 | 21,143,502 | Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. | Br J Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21143502 | PubMed |
| 17 | 11,978,497 | Animal model pharmacokinetics and pharmacodynamics: a critical review. | Int J Antimicrob Agents | 2002 | https://conductscience.org/library/papers/11978497 | PubMed |
| 18 | 28,052,852 | High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28052852 | PubMed |
| 19 | 21,369,876 | Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. | AAPS J | 2011 | https://conductscience.org/library/papers/21369876 | PubMed |
| 20 | 21,769,107 | Implications of augmented renal clearance in critically ill patients. | Nat Rev Nephrol | 2011 | https://conductscience.org/library/papers/21769107 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,787,356 | Source Control in Pseudomonas aeruginosa Bloodstream Infections: An Overlooked Pillar in Reducing 30-Day All-Cause Mortality. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42787356 | PubMed |
| 40,372,038 | A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data. | Microbiol Spectr | 2025 | https://conductscience.org/library/papers/40372038 | PubMed |
| 38,236,031 | Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa. | mBio | 2024 | https://conductscience.org/library/papers/38236031 | PubMed |
| 37,564,179 | Individualized antibiotic dosage regimens for patients with augmented renal clearance. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37564179 | PubMed |
| 36,125,299 | A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36125299 | PubMed |
| 35,924,928 | Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35924928 | PubMed |
| 35,890,380 | The Application of Hollow Fiber Cartridge in Biomedicine. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35890380 | PubMed |
| 35,052,977 | Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35052977 | PubMed |
| 34,156,288 | Filamentous Bacteriophages and the Competitive Interaction between Pseudomonas aeruginosa Strains under Antibiotic Treatment: a Modeling Study. | mSystems | 2021 | https://conductscience.org/library/papers/34156288 | PubMed |
| 32,131,897 | Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients. | BMC Pharmacol Toxicol | 2020 | https://conductscience.org/library/papers/32131897 | PubMed |
| 31,636,062 | Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31636062 | PubMed |
| 30,912,119 | Pharmacodynamic Drug-Drug Interactions. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30912119 | PubMed |
| 30,104,278 | Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/30104278 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29463528
GET https://conductscience.org/api/papers/v1/29463528/references?page=2